L-Asparagine

L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia[1][2][3][4][5].

Product Specifications

CAS Number

[70-47-3]

Product Name Alternative

(-) -Asparagine; Asn; Asparamide

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; DNA/RNA Synthesis; Endogenous Metabolite

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/L-Asparagine.html

Purity

98.0

Solubility

H2O : 6.67 mg/mL (ultrasonic)

Smiles

N[C@H](C(O)=O)CC(N)=O

Molecular Formula

C4H8N2O3

Molecular Weight

132.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Batool T, et al. A Comprehensive Review on L-Asparaginase and Its Applications. Appl Biochem Biotechnol. 2016 Mar;178 (5) :900-23.|[2]Asselin BL, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989 Aug 1;49 (15) :4363-8.|[3]Horvath TD, et al. Assessment of l-Asparaginase Pharmacodynamics in Mouse Models of Cancer. Metabolites. 2019 Jan 9;9 (1) :10.|[4]Kravtzoff R, et al. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in-vivo studies. J Pharm Pharmacol. 1990 Jul;42 (7) :473-6.|[5]Ilaria M Michelozzi, et al. Acute myeloid leukaemia niche regulates response to L-asparaginase. Br J Haematol. 2019 Aug;186 (3) :420-430. doi: 10.1111/bjh.15920.